Home » Chief Financial Officer
- December 05, 2017
Ryboquin, a Scottish Borders-based pharmaceutical company, is currently developing a cancer gene therapy drug. Research and development work is underway into a novel gene therapy employing cutting edge nano-technology which may have the potential to treat several forms of cancer. Ryboquin ECP-102 is a Tumour Apoptosis Enhancer (TAE). This new class of drugs is designed to make chemotherapy many times more effective.
Scale up work is being carried out by the University of Strathclyde’s Institute of Pharmacy and Biomedical Sciences and the company hopes to raise further significant investment during the year to fund further clinical trials and corporate expansion.
Ryboquin is seeking a CFO to support the CEO in raising funds, presenting to investors and managing the operational finances of the business. It is envisaged that the requirement will initially be for c.2 days per week, rising to full time at the end of 2017 as the business continues to grow and looks to secure a significant acquisition.
We are not necessarily looking for candidates with a background in BioTech, but an ability to develop a working understanding of the processes and the industry is desirable.
Candidates should be credible, experienced Finance Directors with a flexible and hands-on approach.
To apply, please email your CV to Ailsa Sutherland, Director, FWB Park Brown at firstname.lastname@example.org
- Central Scotland